Close

Apotex launches generic Lipitor

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Senate Draft Cuts to Medicaid and CHIP Criticized

The American Medical Association has spoken out against the...

Alterations In US Healthcare System Likely in Trump 2.0

Apparently, there is one of the analysts who has...

China’s AI Doctors Revolutionize Healthcare with First AI Hospital

China recently announced a ground-breaking development: the world's first...

Low-Carbon Inhalers Approved for COPD Treatment in the UK

According to AstraZeneca, the Medicines and Healthcare Products Regulatory...

Apotex Inc, a Canadian owned pharmaceutical company with headquarters in Toronto, launched today Apo-Atorvastatin, a generic version of ‘Lipitor(R)’ produced by Pfizer(R). This is the largest product to be genericized in Canadian history with approximate yearly sales of $1.2 billion. This last patent onLipitor(R) will not expire until 2022. Apotex Inc. invented its own crystal form, thus overcoming the patents, 12 years ahead of time, which will result in close to $7 billion of cost-savings for the Canadian healthcare system.

"This is a historical moment as Provincial governments are struggling with increasing deficits. In the last 35 years, Apotex has been leading the way in bringing affordable medicines for consumers" stated Jack Kay, Apotex President and COO. The risks for companies like ours to develop products and to litigate are huge, but the real beneficiaries are the public and private payers and consumers" concluded Mr. Kay.

Apotex spent many years and many millions of dollars on the development and litigation processes for this product.

Apo-Atorvastatin is a 100% Canadian made product including not only Research & Development and tablet manufacturing, but also chemical synthesis.

Latest stories

Related stories

Senate Draft Cuts to Medicaid and CHIP Criticized

The American Medical Association has spoken out against the...

Alterations In US Healthcare System Likely in Trump 2.0

Apparently, there is one of the analysts who has...

China’s AI Doctors Revolutionize Healthcare with First AI Hospital

China recently announced a ground-breaking development: the world's first...

Low-Carbon Inhalers Approved for COPD Treatment in the UK

According to AstraZeneca, the Medicines and Healthcare Products Regulatory...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back